Catalog No.: PC-49284Not For Human Use, Lab Use Only.
BML-277 (BML277) is a potent, selective and ATP-competitive inhibitor of Chk2 serine/threonine kinase with IC50 of 15 nM, >1000-fold selectivity over Chk1 and Cdk1/B kinases.
BML-277 (BML277) is a potent, selective and ATP-competitive inhibitor of Chk2 serine/threonine kinase with IC50 of 15 nM, >1000-fold selectivity over Chk1 and Cdk1/B kinases.
BML-277 dose dependently protects human CD4+ and CD8+ T-cells from apoptosis due to ionizing radiation.
BML-277 specifically inhibit CHK2 phosphorylation at Thr68 at different time course, but not CHK1 phosphorylation.
BML-277 significantly promoted pneumonia symptoms, including mortality, lung infiltration of immune cells, and the abundance of lung pro-inflammatory cytokines in vivo.
BML-277 reduced protein poly(ADP-ribosyl)ation (PARylation), FANCD2 monoubiquitination, homologous recombination and OR CRC cell growth in vitro and in vivo.
